What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Surgery
- Diabetes mellitus
Anthony C Keech spends much of his time researching Internal medicine, Surgery, Cardiology, Placebo and Myocardial infarction.
His work carried out in the field of Internal medicine brings together such families of science as Diabetes mellitus and Endocrinology.
His Pulmonary embolism study in the realm of Surgery connects with subjects such as Hip fracture.
His Cardiology research includes elements of Tunica media, Absolute risk reduction, Disease and Risk factor.
Anthony C Keech has included themes like Rate ratio, Regimen and Pravastatin in his Myocardial infarction study.
Anthony C Keech focuses mostly in the field of Cholesterol, narrowing it down to matters related to Statin and, in some cases, Alirocumab.
His most cited work include:
- Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. (5429 citations)
- Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels (4595 citations)
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. (3734 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Internal medicine, Cardiology, Diabetes mellitus, Fenofibrate and Type 2 diabetes.
His work on Myocardial infarction and Cholesterol as part of general Internal medicine study is frequently linked to In patient, bridging the gap between disciplines.
His Myocardial infarction research incorporates elements of Stroke and Surgery.
In his study, which falls under the umbrella issue of Cardiology, Clinical endpoint is strongly linked to Evolocumab.
His Diabetes mellitus research includes themes of Intervention, Creatinine, Gastroenterology and Kidney disease.
His study explores the link between Fenofibrate and topics such as Diabetic retinopathy that cross with problems in Retinopathy.
He most often published in these fields:
- Internal medicine (82.84%)
- Cardiology (35.24%)
- Diabetes mellitus (35.70%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (82.84%)
- Cardiology (35.24%)
- Diabetes mellitus (35.70%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Cardiology, Diabetes mellitus, Evolocumab and Type 2 diabetes are his primary areas of study.
The PCSK9, Fenofibrate and Myocardial infarction research Anthony C Keech does as part of his general Internal medicine study is frequently linked to other disciplines of science, such as In patient, therefore creating a link between diverse domains of science.
Anthony C Keech combines subjects such as Stroke, Ezetimibe, Randomized controlled trial and Relative risk with his study of Myocardial infarction.
His study in the fields of Revascularization, Percutaneous coronary intervention and Coronary artery disease under the domain of Cardiology overlaps with other disciplines such as Intima-media thickness.
His work in Diabetes mellitus addresses issues such as Gastroenterology, which are connected to fields such as Glycemic.
His studies in Evolocumab integrate themes in fields like PCSK9 Inhibitors and Cognition.
Between 2017 and 2021, his most popular works were:
- Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials (219 citations)
- Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. (201 citations)
- Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER. (114 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Diabetes mellitus
- Disease
The scientist’s investigation covers issues in Internal medicine, PCSK9, Evolocumab, Randomized controlled trial and Diabetes mellitus.
His Internal medicine study frequently draws connections to adjacent fields such as Endocrinology.
His study in PCSK9 is interdisciplinary in nature, drawing from both Statin and Proprotein convertase.
His Evolocumab research is multidisciplinary, relying on both Interquartile range, Cognition and Cardiology.
His Randomized controlled trial research is multidisciplinary, incorporating perspectives in Psychological intervention, Clinical trial, Family medicine, Emergency medicine and Placebo.
His Diabetes mellitus study incorporates themes from Insulin and Macular edema.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
